Hims & Hers faces investigation over alleged securities violations.

• Bloomberg investigates Hims & Hers Health for securities law violations • Misleading statements and undisclosed information under scrutiny • Novo Nordisk terminates collaboration with Hims & Hers due to illegal compounding and deceptive marketing • FDA resolves Wegovy shortage, supports transition to authentic Wegovy through NovoCare Pharmacy • Investigation ongoing

Hims & Hers Health, Inc. (HIMS), a telehealth company, is facing securities lawsuits following allegations of misleading statements and undisclosed information. The lawsuits, filed by Levi & Korsinsky, LLP and Hagens Berman, allege that Hims & Hers engaged in deceptive marketing of Wegovy®, a weight loss drug, which led to the termination of its collaboration with Novo Nordisk [1][2][3].

The complaints allege that Hims & Hers promoted and sold illegitimate, knockoff versions of Wegovy®, putting patient safety at risk. This deceptive marketing resulted in a substantial risk that the company's collaboration with Novo Nordisk would be terminated. As a result, the company's positive statements about its business, operations, and prospects were materially misleading and lacked a reasonable basis [1][2].

The lawsuits follow an announcement by Novo Nordisk that it terminated its collaboration with Hims & Hers due to concerns about the company's sales and deceptive marketing of Wegovy®. This announcement led to a 30% crash in Hims & Hers shares [3].

Hims & Hers investors who purchased or otherwise acquired securities between April 29, 2025, and June 23, 2025, may be eligible to join the class action lawsuit. If you suffered a loss during this period, you have until August 25, 2025, to request that the Court appoint you as lead plaintiff. There is no cost or obligation to participate, and you may be entitled to compensation without payment of any out-of-pocket costs or fees [1][2].

The FDA has since resolved the Wegovy shortage and supports the transition to authentic Wegovy through NovoCare Pharmacy. The investigation into Hims & Hers' marketing practices is ongoing [3].

References:
[1] https://www.prnewswire.com/news-releases/hims--hers-health-inc-sued-for-securities-law-violations--investors-should-contact-levi--korsinsky-before-august-25-2025-to-discuss-your-rights--hims-302502926.html
[2] https://www.morningstar.com/news/pr-newswire/20250711ny28338/hims-hers-health-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-hims
[3] https://www.globenewswire.com/news-release/2025/07/14/3115002/32716/en/Hims-Hers-Health-Inc-HIMS-Faces-Securities-Class-Actions-After-Novo-Nordisk-Cancels-Partnership-Over-Deceptive-Marketing-of-Wegovy-Hagens-Berman.html